LONDON – Cellzome Ltd. signed its second big deal with GlaxoSmithKline plc, agreeing on a €475 million (US$644.3 million) collaboration to apply its epigenetics platform technology in the discovery of oral small-molecule drugs for treating immuno-inflammatory diseases. (BioWorld International) BioWorld International Correspondent Read More
